While neither mRDT + ASP nor CONV + ASP required infectious diseases consults for positive blood cultures, both groups required infectious diseases consults to order the novel beta-lactam/beta-lactamase inhibitor combinations (e.g., ceftazidime-avibactam) included as effective and optimal therapy in this study. The gene discussed is LACTB; the disease is infectious disease.